Drug Trial Radar · NCT06130345
Post-marketing Safety of Elasomeran/Davesomeran and Andusomeran
Last checked: Nov 19, 2026Latest source record: Dec 19, 2024 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
15,196,685
Actual
Start
Apr 14, 2023
Primary completion
Feb 29, 2024
Study completion Aug 31, 2024
Sponsor
- Lead sponsor
- ModernaTX, Inc.Moderna (MRNA)
- Sponsor type
- Industry
- Collaborators
- Aetion, Inc.
- First posted
- Nov 14, 2023
Design
- Study type
- Observational
- Who can join
- All sexes
- Healthy volunteers
- Yes
Summary
As written by the sponsor on the registry.
The main objective of the study is to evaluate the safety of the elasomeran/davesomeran and andusomeran vaccines as used in routine clinical practice.
Conditions
- SARS-CoV-2
Interventions
SPIKEVAXBiological
Intramuscular injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Number of Participants With Adverse Events of Special Interest (AESI)Time frame: Day 2 up to Day 60 after vaccination
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Aetion, Inc
New York, New York
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.